Simplex Trading’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $141K | Sell |
15,900
-48,300
| -75% | -$566K | ﹤0.01% | 4694 |
|
|
2025
Q4 | $955K | Sell |
64,200
-13,300
| -17% | -$232K | ﹤0.01% | 2660 |
|
|
2025
Q3 | $1.49M | Buy |
77,500
+11,600
| +18% | +$185K | ﹤0.01% | 2626 |
|
|
2025
Q2 | $732K | Buy |
65,900
+63,295
| +2,430% | +$557K | ﹤0.01% | 3118 |
|
|
2025
Q1 | $36K | Sell |
2,605
-9,320
| -78% | -$146K | ﹤0.01% | 6092 |
|
|
2024
Q4 | $198K | Buy |
11,925
+2,295
| +24% | +$37.3K | ﹤0.01% | 4530 |
|
|
2024
Q3 | $182K | Sell |
9,630
-4,045
| -30% | -$82.1K | ﹤0.01% | 4604 |
|
|
2024
Q2 | $198K | Buy |
13,675
+9,790
| +252% | +$163K | ﹤0.01% | 4659 |
|
|
2024
Q1 | $60K | Buy |
3,885
+2,880
| +287% | +$62.1K | ﹤0.01% | 6100 |
|
|
2023
Q4 | $28K | Sell |
1,005
-8,955
| -90% | -$235K | ﹤0.01% | 6630 |
|
|
2023
Q3 | $474K | Buy |
9,960
+3,765
| +61% | +$287K | ﹤0.01% | 3467 |
|
|
2023
Q2 | $593K | Buy |
6,195
+5,710
| +1,177% | +$621K | ﹤0.01% | 3132 |
|
|
2023
Q1 | $54K | Sell |
485
-835
| -63% | -$90.3K | ﹤0.01% | 5835 |
|
|
2022
Q4 | $147K | Sell |
1,320
-3,685
| -74% | -$494K | ﹤0.01% | 4613 |
|
|
2022
Q3 | $642K | Buy |
5,005
+3,830
| +326% | +$392K | ﹤0.01% | 3173 |
|
|
2022
Q2 | $80K | Sell |
1,175
-65
| -5% | -$5.6K | ﹤0.01% | 5868 |
|
|
2022
Q1 | $176K | Sell |
1,240
-395
| -24% | -$60.8K | ﹤0.01% | 5336 |
|
|
2021
Q4 | $272K | Sell |
1,635
-285
| -15% | -$45.3K | ﹤0.01% | 4725 |
|
|
2021
Q3 | $867K | Sell |
1,920
-1,545
| -45% | -$302K | ﹤0.01% | 3276 |
|
|
2021
Q2 | $1.65M | Buy |
3,465
+3,414
| +6,694% | +$1.44M | ﹤0.01% | 2431 |
|
|
2021
Q1 | $2.1M | Buy |
51
+49
| +2,450% | +$22.6K | ﹤0.01% | 1554 |
|
|
2020
Q4 | $90K | Sell |
2
-1
| -33% | -$586 | ﹤0.01% | 5547 |
|
|
2020
Q3 | $195K | Sell |
3
-27
| -90% | -$8.98K | ﹤0.01% | 4141 |
|
|
2020
Q2 | $289K | Buy |
30
+29
| +2,900% | +$2.54K | ﹤0.01% | 3570 |
|
|
2020
Q1 | $3K | Buy |
+1
| New | +$67 | ﹤0.01% | 7073 |
|
|
2019
Q4 | – | Sell |
-2
| Closed | -$12K | – | 7677 |
|
|
2019
Q3 | $12K | Buy |
+2
| New | +$132 | ﹤0.01% | 6149 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6882 |
|
|
2019
Q1 | – | Hold |
0
| – | -$4K | – | 7542 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6321 |
|
|
2018
Q3 | – | Sell |
-1
| Closed | -$162 | – | 6681 |
|
|
2018
Q2 | $9K | Buy |
+1
| New | +$163 | ﹤0.01% | 6401 |
|
|
2018
Q1 | – | Sell |
-2
| Closed | -$3K | – | 6554 |
|
|
2017
Q4 | $3K | Hold |
2
| – | – | ﹤0.01% | 4923 |
|
|
2017
Q3 | $25K | Sell |
2
-1
| -33% | -$273 | ﹤0.01% | 2945 |
|
|
2017
Q2 | $16K | Sell |
3
-8
| -73% | -$1.64K | ﹤0.01% | 3527 |
|
|
2017
Q1 | $17K | Sell |
11
-2
| -15% | -$406 | ﹤0.01% | 3419 |
|
|
2016
Q4 | $18K | Buy |
13
+8
| +160% | +$1.75K | ﹤0.01% | 3128 |
|
|
2016
Q3 | $5K | Hold |
5
| – | – | ﹤0.01% | 4285 |
|
|
2016
Q2 | $27K | Buy |
+5
| New | +$2.93K | ﹤0.01% | 2630 |
|
Other funds holding MCRB
FP
VCM
VFT
Simplex Trading's MCRB Position: Q1 2026 in Review
Simplex Trading increased its Seres Therapeutics (MCRB) stake by 149% in Q1 2026, buying an estimated $21.5K and bringing the position to 3,070 shares worth $27.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6489.
Simplex Trading first reported a position in MCRB in Q3 2015 and has held it in 25 quarters since. The position peaked at $1.4M in Q3 2021. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.
- Simplex Trading held 3,070 shares of Seres Therapeutics worth $27.2K as of Q1 2026.
- Simplex Trading bought 1,838 Seres Therapeutics shares in Q1 2026, an estimated $21.5K.
- Seres Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #6489 holding.
- Simplex Trading first reported a position in Seres Therapeutics in Q3 2015 and has held it in 25 quarters since.
- Simplex Trading's Seres Therapeutics position peaked at $1.4M in Q3 2021.
- 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.
Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.